Cytochrome P450 2C8 (CYP2C8) plays a major role in the metabolism of therapeutically important drugs which exhibit large interindividual differences in their pharmacokinetics. In order to evaluate any genetic influence on this variation, a CYP2C8 phenotype-genotype evaluation was carried out in Caucasians. Two novel CYP2C8 haplotypes, named B and C with frequencies of 24 and 22% in Caucasians, respectively, were identified and caused a significantly increased and reduced paclitaxel 6a-hydroxylation, respectively, as evident from analyses of 49 human liver samples. In healthy white subjects, CYP2C8*3 and the two novel haplotypes significantly influenced repaglinide pharmacokinetics in SLCO1B1c.521T/C heterozygous individuals: haplotype B was associated with reduced and haplotype C with increased repaglinide AUC (0-N). Functional studies suggested À271C4A (CYP2C8*1B) as a causative SNP in haplotype B. In conclusion, two novel common CYP2C8 haplotypes were identified and significantly associated with altered rate of CYP2C8-dependent drug metabolism in vitro and in vivo.
Introduction
Cytochrome P450 2C8 (CYP2C8) is a drug-metabolizing enzyme mainly expressed in the liver but also present in the gastrointestinal tract, kidney, adrenal gland and tonsils.
1 CYP2C8 plays a major role in the metabolism of several clinically important therapeutic drugs such as amiodarone, amodiaquine, dapsone, loperamide, paclitaxel, pioglitazone, repaglinide, rosiglitazone and verapamil. [2] [3] [4] [5] In addition, CYP2C8 oxidizes the endogenous substrate arachidonic acid to vasoactive epoxyeicosatrienoic acids and it has been proposed that CYP2C8 might be relevant for cardiovascular disease processes. 6, 7 There is a large interindividual variation in the metabolism of CYP2C8-specific substrates and in CYP2C8 expression, 8 which is likely to influence the therapeutic or adverse outcome of drugs metabolized by CYP2C8. For example, CYP2C8 is a key enzyme in the metabolic pathway of cerivastatin, 9, 10 which was withdrawn from the market in 2001 because of a high risk of myotoxicity. Gemfibrozil, a potent inhibitor and inactivator of CYP2C8 greatly increased the plasma concentrations of cerivastatin and the risk of rhabdomyolysis. 11 Clinically relevant interindividual differences in CYP2C8 activity might be the result of CYP2C8 gene polymorphisms. To date, several CYP2C8 variant proteins caused by single nucleotide polymorphisms (SNPs) have been described (see http://www.cypalleles.ki.se), although no common deleterious allelic variant has been identified. 10, [12] [13] [14] Paclitaxel 6a-hydroxylation is commonly used as a marker reaction for CYP2C8 activity in vitro. Paclitaxel is metabolized by P450s in the liver, mainly by CYP2C8 (6a-hydroxylation) and also by CYP3A4 (C'3-hydroxylation). 15 Several lines of evidence are in support of CYP2C8 being the major catalyst of 6a-hydroxylation of paclitaxel, such as the correlation between the formation of 6aÀOH-paclitaxel and the hepatic CYP2C8 protein content and in addition the formation of other metabolites formed by CYP2C8. 16, 17 Furthermore, the selective and potent in vitro CYP2C8-inhibitor montelukast which inhibits several CYP2C8-specific reactions, such as amodiaquine N-deethylase, rosiglitazone N-demethylase, also effectively inhibits paclitaxel 6a-hydroxylase. 18 In the present study, we conducted a systematic investigation about CYP2C8 genetic variation and its impact on CYP2C8 phenotype. Using data from the International HapMap Project and direct genotyping of 54-unrelated human samples, the common CYP2C8 Caucasian haplotypes were inferred. The data were used to perform haplotype-phenotype association studies using a human liver panel in which CYP2C8 activity and expression levels were characterized and repaglinide pharmacokinetics data obtained from white healthy volunteers. Two novel CYP2C8 haplotypes (named B and C) which might explain part of the interindividual differences in CYP2C8 activity were found.
Results
CYP2C8 interindividual variation affects hepatic CYP2C8 mRNA and protein content and in vitro paclitaxel 6a-hydroxylation To identify major factors contributing to CYP2C8 interindividual variation we used a human liver panel (n ¼ 54). The activity of CYP2C8 was determined by measuring the CYP2C8-specific paclitaxel 6a-hydroxylation. The CYP2C8 inter-sample variation was 190-and 23-fold at the level of mRNA and protein content, respectively, and 34-fold at the level of activity. A correlation between CYP2C8 mRNA and protein content was found, suggesting that the variable CYP2C8 protein expression levels could be controlled by a pretranslational mechanism. Similarly, the CYP2C8 protein content essentially paralleled the rate of paclitaxel 6a-hydroxylation (Figures 1a and b) .
Neither gender nor age influenced CYP2C8 expression (data not shown). Interestingly, an alternatively spliced CYP2C8 mRNA carrying the full sequence of intron 2 was detected by RT-PCR (data not shown). The relative levels of the splicing products were however similar in all samples (data not shown), suggesting that the alternative splicing is not the cause for the interindividual CYP2C8 variation.
Identification of the common Caucasian CYP2C8 haplotypes Using the HapMap Project CEPH data we found that the CYP2C8 gene was included in one single haplotype block in Caucasians (Supplementary Figure 1a) and that CYP2C8 diversity was captured by seven common haplotypes (frequency 42%). A total of 12 CYP2C8 SNPs (HapMap tagging SNPs (tSNPs) and CYP2C8 SNPs with a putative functional role: located in coding regions, proximal promoter and near splicing sites) were selected and genotyped by allele-specific PCR or RFLP in 54-unrelated Caucasian liver samples, CYP2C8 haplotypes were inferred and then compared to HapMap data. The results were very similar to HapMap, and seven common CYP2C8 haplotypes were also identified and named: A, B, C1, C2, C3, D and E ( Table 1 ). The major difference between HapMap and the haplotypes predicted with the liver samples consisted in HapMap haplotype F which was almost absent in the livers (0.4% frequency) and CYP2C8*4 (not present in HapMap database) which differentiated haplotypes C1 and C2. Asians and Africans showed important variations in the CYP2C8 haplotype blocks, haplotypes and in the frequency of CYP2C8 SNPs, for example, haplotype D (CYP2C8*3) was only detected in Caucasians (Supplementary Figure 2) . Two CYP2C8 haplotypes show an altered phenotype in vitro and in vivo Livers carrying the variant alleles, CYP2C8*3 and CYP2C8*4 causing amino acid substitutions, did not show a significantly altered paclitaxel 6a-hydroxylation in comparison to CYP2C8*1/*1 livers. There were 13 CYP2C8*3 and 8 CYP2C8*4 heterozygous from a total of 49 liver samples, and the mean activity after excluding from the analysis one sample carrying simultaneously *3 and *4 alleles was 39.8, 30.2 and 31.8 6a-hydroxypaclitaxel ng per min per mg protein, for CYP2C8*1/*1, CYP2C8*1/*3 and CYP2C8*1/*4 samples, respectively, with no significant differences. These results suggest that these variants do not have a large impact on paclitaxel 6a-hydroxylation, but further studies including homozygous samples and larger numbers should clarify this.
We then compared the CYP2C8 activity (measured by paclitaxel 6a-hydroxylation) and the CYP2C8 haplotypes of the liver samples (n ¼ 49), and found that neither haplotypes A and D, nor E showed a significantly different activity (data not shown). On the other hand, haplotype B was associated with an increased paclitaxel metabolism and haplotype C (grouping together C1, C2 and C3) with a lower activity. When the liver samples carrying CYP2C8 haplotypes B and C (cases simultaneously carrying both haplotypes excluded from these groups) were compared to the other samples, a statistically significant difference was found for CYP2C8 activity and protein content (Figure 2) . None of the three C haplotypes C1, C2 and C3, when analyzed individually, showed any significant difference in paclitaxel hydroxylation activity. These data highlight CYP2C8 haplotypes B and C as possible factors contributing to CYP2C8 interindividual variability, and suggest that alterations at the enzyme expression level rather than alterations of the enzyme activity could cause the observed differences.
To further evaluate the significance of the in vitro CYP2C8 haplotype-phenotype findings, we carried out an analysis of repaglinide pharmacokinetics in 68 white healthy volunteers in relation to the CYP2C8 haplotypes ( Figure 3 and Supplementary Figure 3) . Because the coding SNP 521T4C in the SLCO1B1 gene (Val174Ala; OATP1B1) influences the pharmacokinetics of repaglinide to a large extent, the data Table 1 The frequencies of each haplotype are shown, the seven most common haplotypes accounting for 92% of all predicted haplotypes.
c
The ancestral sequence is that from Pan Troglodytes.
were stratified for this SNP. In subjects heterozygous for CYP2C8 cs/ β-actin mRNA (ru) Figure 2 Association between CYP2C8 haplotypes and phenotype in a human liver panel. Liver samples were classified according to their CYP2C8 haplotypes and compared to (a) CYP2C8 activity (paclitaxel 6a-hydroxylation); (b) CYP2C8 protein content (CYP2C8 pmol per mg microsomal protein) and (c) amounts of correctly spliced CYP2C8 mRNA normalized with b-actin content (relative units (ru)). The horizontal bars show median values for each genotype group. The P-value for the oneway ANOVA test is shown if o0.05. In addition, two-tailed t-test was significant for Hap B vs Hap C at activity and protein level (P ¼ 0.029 and P ¼ 0.014, respectively) and for Hap C vs others at activity and protein level (P ¼ 0.029 and P ¼ 0.018, respectively). Subjects homozygous for the CYP2C8 haplotypes B and C are shown in white. Figure 3) . The number of individuals with the SLCO1B1 521CC genotype was insufficient to perform statistical analysis with respect to CYP2C8 haplotypes.
Low activity

CYP2C8*1B is a causal SNP in haplotype B
Despite the high sequence similarity between haplotypes B and E, only haplotype B showed an altered CYP2C8 activity.
Because the results presented above, suggest that the rate of transcription might be causative for the interindividual differences in CYP2C8 expression, we focused on haplotype B promoter SNPs: rs7909236 (CYP2C8*1B) and rs11188172, located at À271 and À2048 from the translational start, respectively. Electrophoretic mobility shift assays (EMSAs) showed that a high-affinity protein-DNA-specific complex was formed using the CYP2C8*1B probe and that the nuclear proteins had higher affinity for the CYP2C8*1B element as compared to the wild-type CYP2C8*1 sequence (Figure 4a ). The À2048 SNP was located in an element similar to a CAR/ PXR site (À2056). However, previous work showed that this site is not functional and cannot bind CAR or PXR. 19 Similarly, when we performed EMSA experiments with probes containing rs11188172 at À2048, no specific binding complex could be detected neither for the wild type nor the variant allele (data not shown).
To further investigate CYP2C8*1B functionality, we cloned the À361/À1 CYP2C8 promoter region corresponding to CYP2C8*1 (À271C) and CYP2C8*1B (À271A) into luciferase reporter plasmids. Transfection of these constructs in the hepatic cell line HepG2 resulted in no differences in luciferase activity (data not shown). However, these cells hardly express CYP2C8, suggesting that HepG2 might lack transcriptional factors crucial for CYP2C8 transcription. Thus, we transfected the plasmids into mice liver which contains high levels of hepatic transcription factors. As shown in Figure 4b , CYP2C8*1B was able to drive transcription at higher rates than CYP2C8*1 (1.8-fold increase, Po0.05). Together all these data suggest that CYP2C8 À271C4A is a functional polymorphism causing increased activity of haplotype B.
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Luciferase activity (ru) Figure 4 CYP2C8*1B results in an increased binding of nuclear proteins and higher transcription rate. (a) EMSA experiments using double-stranded oligonucleotides expanding the À260/À284 region of CYP2C8 promoter were performed as described in the Materials and Methods section. The competition experiments were performed using 5-, 25-or 50-fold excess of cold double-stranded oligonucleotides corresponding to À271C (*1) or À271A (*1B) and the DNA-labeled probe corresponded either to CYP2C8*1 (À271C) or CYP2C8*1B (À271A). Specific protein complex (S), nuclear extracts (NE), free probe (FP). (b) Transcriptional analysis of the CYP2C8 proximal promoter by in vivo mouse liver transfections. A total of 10 mg of CYP2C8 promoter constructs (À368/À1) and 100 ng of pRL-SV40 were injected into the tail vein of male CD1 mice. After 24 h, the liver was homogenized and used to measure firefly and Renilla luminescence. The values given represent luminescence normalized mean values7s.d. The number between parentheses indicates the number of mice used with each construct. Statistical differences were evaluated using two-tailed t-test.
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Discussion
This study compared CYP2C8 genetic variation with in vitro and in vivo CYP2C8 phenotype data in order to elucidate the basis for the interindividual variation in CYP2C8 activity. We inferred the common Caucasian CYP2C8 haplotypes and found that two of them (named B and C) showed an altered in vitro paclitaxel metabolism using human liver samples. This effect was also found in vivo with repaglinide in SLCO1B1 521T/C heterozygous individuals: repaglinide AUC (0-N) was significantly lower for haplotype B carriers and significantly higher for haplotype C carriers, corresponding to the paclitaxel 6a-hydroxylation rates in the liver samples (compare Figures 2 and 3 ). In addition, in the SLCO1B1 521T/C heterozygous subjects, we also found that haplotype D (CYP2C8*3) showed a significantly decreased repaglinide AUC (0-N). However, for the SLCO1B1 521T/T homozygous healthy volunteers (with the highest hepatic repaglinide uptake), the individual effects of the CYP2C8 haplotypes and CYP2C8*3 were hindered, possibly because of the greater impact of CYP3A4 on repaglinide metabolism at higher drug concentrations. 4 Nevertheless, the repaglinide AUC(0-N) of individuals carrying simultaneously two high activity haplotypes (B and/or D) was lower than that of individuals carrying none or only 1 or none of these alleles (P ¼ 0.05).
The impact of CYP2C8*3 on drug metabolism is still ambiguous. Our study confirms previous pharmacokinetic data showing an increased activity for CYP2C8*3, 20-22 but this is in contrast to the lack of effect or decreased activity found for CYP2C8*3 in in vitro studies using human liver microsomes or recombinant CYP2C8.3 protein. 8, 13, 16, 23, 24 A number of explanations have been proposed for these contradictions, such as differences in CYP2C8.3 enzymatic activity depending on the substrate since a variety of substrates have been used, or studies with small sample sizes. Our in vitro work using paclitaxel fails to find any effect of CYP2C8*3. However, in a sample set with CYP2C8*3 homozygous, a relationship might have been evident. In contrast, the CYP2C8 haplotypes B and C exhibited the same effect in vitro with paclitaxel and in vivo with repaglinide. Despite that the allele frequency of the two novel CYP2C8 haplotypes, B and C, was relatively high (24 and 22%, respectively, calculated with the 122 Caucasian samples included in the study), the number of subjects homozygous for haplotypes B and C was low in our study resulting in an underpowering effect of the haplotypes and hence rendering it difficult to calculate the difference in CYP2C8 drug metabolism for these individuals. Thus, further studies are needed to fully evaluate the clinical impact of the novel CYP2C8 haplotypes, as well as CYP2C8*3, on CYP2C8-dependent drug metabolism.
In addition, we tried to find the functional SNPs within the CYP2C8 haplotypes. Since there is one single haplotype block within the CYP2C8 gene in Caucasians, all SNPs are in linkage disequilibrium and the causative SNPs could be located anywhere within the gene (Supplementary Figure 1) . However, we focused on haplotype B-specific promoter SNPs because previous data suggested that mRNA levels are important for CYP2C8 interindividual variation. We tested these SNPs using EMSA analysis and plasmid mice transfection, and found that CYP2C8*1B affected both transcription factor binding and promoter activity (Figure 4) , thus, suggesting that this is a causative SNP within haplotype B. With respect to inter-ethnic differences, in Asians and Africans, there are two and three haplotype blocks within CYP2C8 gene, respectively, and the frequency of some CYP2C8 SNPs is very different from Caucasians: CYP2C8*3 (Haplotype D) is absent in Asians and Africans, and CYP2C8*1B is also found in Asians but is not associated to any specific haplotype because of its location in a recombination region (Supplementary Figure 2) .
An optimized therapy for drugs metabolized by CYP2C8 might require the identification of individuals with higher risk of adverse drug reactions, due to a reduced rate of metabolism, and of those who might need higher drug doses, due to an increased metabolism. This is particularly warrant for drugs with narrow therapeutic indexes that frequently present serious toxicities such as the anti-cancer drug paclitaxel. In this respect, the genetic variation of CYP2C8 could play an important role and this work provides novel data regarding the relevant polymorphism involved.
In conclusion, the CYP2C8 phenotype shows a large interindividual variability that, to a certain extent, is due to genetic variations predictable by genotyping. The two novel Caucasian CYP2C8 haplotypes identified in this work (named B and C and characterized by rs7909236 (CYP2C8*1B) and rs1113129/rs3216029, respectively: Figure 5 ) might contribute to a better dose optimization by predictive genotyping in patients on therapy with drugs which are CYP2C8 substrates.
Materials and methods
Materials
Protease Inhibitor Cocktail Tablets were from Roche Diagnostics (Mannheim, Germany). Paclitaxel was from Sigma (St Louis, MO, USA) and 6a-hydroxy paclitaxel was from BD Gentest (Woburn, MA, USA). [g-32 P]dATP was purchased from Amersham Biosciences (Freiburg, Germany). Poly(dIdC) was purchased from Pharmacia (Peapack, NJ, USA). The Dual Luciferase Reporter Assay System, the pGL3-Basic firefly luciferase reporter vector and the pRL-SV40 Renilla plasmid were from Promega (Madison, WI, USA). The TransIT in vivo Gene Delivery System kit was from Mirus (Madison, WI, USA).
Human liver material
The characteristics of the 54 livers used in this study have been previously described. 25, 26 All livers were documented to be of Caucasian origin except for one of unknown origin, which showed typical Caucasian haplotype characteristics and was included in the study. The tissues were stored at À70 1C until used to isolate total RNA, genomic DNA and to prepare microsomes by subcellular fractionation.
CYP2C8 haplotypes and altered drug metabolism C Rodríguez-Antona et al Drug pretreatment data from the liver donors showed that in seven cases they had previously taken some CYP3A inducers, which could plausibly affect CYP2C8 levels. We compared the CYP3A4 (previously described) 25, 26 and CYP2C8 activities of the liver samples finding a correlation coefficient of 0.35 and r 2 of 0.13. The CYP2C8 mRNA, protein and activity levels of the livers with no drug induction and of those putatively induced was compared finding in average a 0.8, 1.6 and 1.0-fold difference in the induced livers when compared with the nontreated livers (for CYP3A4 the induced livers showed a 2.5-fold increase in activity). This suggested that for CYP2C8, the possible induction in those seven livers was not a major confounding factor in the study.
RT-PCR for CYP2C8 mRNA quantification and detection of CYP2C8 alternative splicing Total RNA was extracted from the human livers using the QuickPrepTotal RNA Extraction Kit (Amersham Biosciences) and 2 mg of total RNA were reverse transcribed using Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and an oligo dT14 primer. The cDNAs from the human livers were subjected to standard PCR amplification using specific primers. Quantitative real-time PCR assay was carried out with the Smart Cycler (Cepheid, Sunnyvale, CA, USA) using the SyberGreen PCR master mix (PE Applied Biosystems, Foster City, CA, USA) and primers specifically amplifying the correctly spliced or the alternatively spliced CYP2C8 mRNA and b-actin (Supplementary Table 1 ). Aliquots of the PCR reactions were subjected to electrophoresis, for size and purity confirmation. Standard curves were constructed with serial 10-fold dilutions of an accurately determined concentration of a DNA fragment containing the target sequence. Normalization was carried out with the internal standard b-actin.
Immunoblot analysis
Quantification of CYP2C8 protein in human liver microsomes was performed by immunoblotting analysis using the anti-human CYP2C8 antibody from Puracyp (Carlsbad, CA, USA) which does not cross-react with CYP2C9, CYP2C18 or CYP2C19. Basically, western blotting was performed as previously described and following the antibody manufacturer's instructions. 27 The CYP2C8 content was determined from standard curves derived from human CYP2C8 BD Supersomes (BD Gentest). The detection limit under the conditions used was of 2.5 pmol CYP2C8 per mg microsomal protein. Figure 5 Schematic representation of CYP2C8 haplotypes (A, B and C). CYP2C8 gene is represented by a rectangle with the exons in black, the arrows indicate the location of SNPs representative of the haplotypes, the nucleotide change shown below. Haplotype B includes the promoter SNPs: À2014 (rs11188172) and À271 (CYP2C8*1B, rs7909236). Haplotype B also contains rs2275622 in intron 2 and rs2275620 in intron 7, but these are not haplotype B-specific SNPs, since they are also present in haplotype E. Haplotype C includes SNPs in CYP2C8 promoter À370 (rs17110453, 2C8*1C), intron 2 (rs3216029) and intron 5 (rs1113129) and exon 5 (2C8*4, rs1058930). In the case of haplotype C, two SNPs (CYP2C8*1C and CYP2C8*4) are not present in all individuals and the estimated frequencies of these SNPs are shown within brackets.
Assay for paclitaxel 6a-hydroxylase activity Paclitaxel 6a-hydroxylase activity was determined as described previously 23 with slight modifications. The incubation mixture contained 10 mM paclitaxel, 300 mg of microsomal proteins and 1 mM nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) in a final volume of 0.5 ml of 50 mM potassium phosphate buffer (pH 7.4). After preincubation for 1 min at 37 1C, the reaction was started by the addition of NADPH. The mixture was incubated for 40 min at 37 1C, and the reaction was stopped with 3 ml of ethyl acetate. The mixture was spiked with internal standard (4-androstene 3,17-dione) and vigorously vortexed for 5 min. After centrifugation at 5000 g for 10 min, the organic fraction was evaporated under a gentle stream of N 2 gas. High-performance liquid chromatography analysis was performed injecting the samples into a 5 mm 4 Â 250 mm LiChrospher-100 RP-18 column (Merck, Darmstadt, Germany), using a 60:40 methanol:H 2 O (v/v) isocratic mobile phase at a flow rate of 1 ml min À1 and peaks detected by UV absorbance at 229 nm. Quantification of 6a-hydroxy paclitaxel was based on peak area measurements from linear calibration curves obtained with pure reference compounds. The detection limit was 2.5 ng 6a-hydroxy paclitaxel per min per mg protein. Samples incubated without NADPH were used to determine background absorbance. The results presented are the mean of independent microsomal incubations, except for 10 samples where only one incubation could be performed.
CYP2C8 genotyping and sequencing
Genomic DNA from the human livers was prepared using a QIAamp tissue kit (Qiagen GmbH, Hilden, Germany), the final DNA concentration was determined using PicoGreen (Molecular Probes, Leiden, the Netherlands) and 50 ng of DNA were used for each genotyping.
RFLP was used for the genotyping of CYP2C8*1C, CYP2C8*3-R139K, rs1113129, rs11188172 and rs1934956, while allele-specific PCR was used for CYP2C8*1B, CYP2C8*3-K399R, CYP2C8*4, rs2275622, rs3216029, rs2275620 and rs2185571. The oligonucleotides used for CYP2C8 genotyping, the size of the amplified DNA fragment and, in case of RFLP, the restriction enzymes used are listed in Supplementary Table 2 . In general, the amplification conditions for RFLP were 1 min 95 1C, followed by 36 cycles of 30 s at 94 1C, 30 s at 57 1C, 30-60 s at 72 1C and a final extension of 5 min at 72 1C, using the Taq polymerase from Invitrogen. For allele-specific PCRs, the annealing temperatures and number of cycles varied and are available upon request.
Genotyping accuracy was ascertained through direct sequencing of random homozygous wild type, homozygous variant and heterozygous samples using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit and analyzed on an ABI PRISM 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). No deviations from the expected population genotype proportions (predicted by Hardy-Weinberg equilibrium) were detected.
CYP2C8 haplotype inference
The data from the International HapMap project (http:// www.hapmap. org) was used to identify CYP2C8 tSNPs capturing the haplotype diversity of CYP2C8. The SNPs genotype data was dumped from the International HapMap Project 28 and analyzed using Haploview 3.32 (http:// www.broad.mit.edu/personal/jcbarret/haplo/download.php). 29 In Caucasians, CYP2C8 gene was contained in one haplotype block and six tSNPs represented the seven haplotypes with a frequency higher than 0.02 (Supplementary Figure 1) .
In an independent sample series of 54-unrelated Caucasian samples, we inferred CYP2C8 haplotypes by genotyping 12 CYP2C8 SNPs (HapMap tSNPs which are underlined plus additional putatively important CYP2C8 SNPs): the coding SNPs CYP2C8*3 (rs11572080 and rs10509681) and CYP2C8*4 (rs1058930); the promoter SNPs CYP2C8*1B (rs7909236), CYP2C8*1C (rs17110453) and a SNP located in a putative CAR-PXR element at À2048 (rs11188172), two intron 2 SNPs of relatively high frequency IVS2-64G4A (rs2275622) and IVS2-13insT (rs11572078) and SNPs characteristic of different HapMap haplotypes: rs1934956 in intron 1, rs2185571 in intron 3, rs1113129 in intron 5 and rs2275620 in intron 7. In 51 samples, the genotype data was complete for the 12 SNPs and SNPAlyze 4.1 sofware (Dynacom Co., Ltd in Japan) and PHASE program 30, 31 were used for haplotype inference (Table 1) .
Repaglinide pharmacokinetics in relation to CYP2C8 haplotypes in humans in vivo A total of 68 healthy Finnish Caucasian subjects, who had participated in pharmacokinetic studies with repaglinide were included. [32] [33] [34] [35] [36] [37] The studies had been approved by the Ethics Committee for Studies in Healthy Subjects of the Helsinki and Uusimaa Hospital District and the National Agency for Medicines. All subjects had given written informed consent.
After an overnight fast, the subjects ingested a single 0.25-mg dose of repaglinide (one half of a 0.5-mg tablet of Novonorm; NovoNordisk, Bagsvaerd, Denmark) with 150 ml of water at 9 a.m. Repaglinide concentrations were quantified in timed plasma samples for up to 7 h by liquid chromatography-tandem mass spectrometry. The repaglinide AUC(0-N) was calculated as described previously. [32] [33] [34] [35] [36] [37] A 10-ml EDTA blood sample was drawn from each subject and stored at À20 1C prior to genomic DNA extraction with the QIAamp blood DNA mini kit (Qiagen). Of the 68 subjects, 56 had been genotyped for the SLCO1B1c521T4C SNP previously and the remaining 12 were genotyped for that SNP as described previously. 21 In order to assign the corresponding CYP2C8 haplotypes to the subjects, six tSNPs were genotyped: rs7909236 (CYP2C8*1B ¼ haplotype B); rs1113129
(CYP2C8*4 ¼ haplotype C2); rs11572080 (CYP2C8*3 ¼ haplotype D); rs2275622 (intron 2-64G4A ¼ haplotype E when rs7909236 is negative) and haplotype A was assigned when negative for the six SNPs above.
CYP2C8 haplotypes and altered drug metabolism C Rodríguez-Antona et al Preparation of nuclear extracts and electrophoretic mobility shift assay Nuclear extracts from HepG2 cells were prepared as described previously. 38 The double-stranded oligonucleotides corresponding to CYP2C8*1 and CYP2C8*1B were 5 0 -CAGCACATTGGAACAACCAGGGACT-3 0 and 5 0 -CAGCA-CATTGGAAAAACCAGGGACT-3 0 , respectively, and their inverse/complementary sequences. The double-stranded oligonucleotides corresponding to rs11188172 G4A, at À2048 of CYP2C8 were 5 0 -AAACCAAACACGTCTGACCCA CAT-3 0 and 5 0 -AAACCAAACACATCTGACCCACA-3 0 , respectively, and their inverse/complementary sequences. The EMSA binding reactions were carried out with 12 mg of nuclear extract that were preincubated at 37 1C for 20 min in a buffer containing 2 mg of poly(dI/dC), 100 mM of NaCl, 15 mM HEPES pH 7.9, 0.25 mM EDTA, 0.25 mM EGTA, 0.25 mM dithiothreitol and 5% glycerol. The oligonucleotides were radiolabeled using [ 32 P] dATP and T4 polynucleotide kinase (Invitrogen), added to the reaction mixture that had a final volume of 25 ml, and incubated for 30 min at 37 1C. For competition experiments, 5-50-fold excess of unlabeled double-stranded oligonucleotides were added to the reaction mixture before the radiolabeled probe. The binding of proteins to the oligonucleotides was determined by fractionating the reaction mixture by electrophoresis through a nondenaturing 4% polyacrylamide gel at 200 V and 4 1C, using 0.5 Â Tris-borate buffer. Where appropriate, a competitor DNA was included in the preincubation, prior to the addition of the 32 P-labeled DNA. Gels were dried and exposed at À70 1C to an X-ray film with intensifying screens.
Reporter plasmids and in vivo mouse liver cell transfection Fragments of the human CYP2C8 promoter were amplified with the Elongase Enzyme Mix (Invitrogen) using genomic DNA from individuals homozygous for the wild type or the CYP2C8*1B allele. The primers used were 5 0 -GTCACTC GAGCCCAACTGGTCATTAATCTGAGAATAT-3 0 that contains an XhoI restriction enzyme site underlined, and 5 0 -AAGGAAGCTTTGAAGCCTTCTCTTCTTATTAAGACAG-3 0 that contains a HindIII restriction enzyme site underlined. The amplified DNA fragments containing from À368 to À1 of CYP2C8 promoter ( þ 1 refers to the translation start site) were cloned in the promoterless pGL3-Basic firefly luciferase reporter vector and sequenced to rule out PCR artifacts. For in vivo cell transfection, 20-22 g male CD1 mice were transfected through tail injection with 10 mg of the CYP2C8 constructs and 100 ng of pRL-SV40, in volumes of 2.0-2.2 ml in less than 8 s using the TransIT in vivo gene delivery system kit as previously described. 39 After 24 h, animals were killed and the liver was removed and homogenized to measure firefly and Renilla luminescence. Two independent experiments were performed using two different maxipreps for each construct, and with a total number of at least 15 mice for each construct. The study was approved by the ethics committee for animal experiments at Karolinska Institutet, Stockholm.
Statistical analysis
Data were analyzed using GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San Diego, CA, USA (http://www.graphpad.com). The method of KolmogorovSmirnov was used to test for normality, and when it indicated normality, parametric tests were used. One-way analysis of variance with Tukey-Kramer post-test was used for multiple comparisons. Differences were considered significant when P-values were less than 0.05. 
